Emtricitabine
- Generic Name
- Emtricitabine
- Brand Names
- Atripla, Biktarvy, Complera, Descovy, Emtriva, Genvoya, Odefsey, Stribild, Truvada
- Drug Type
- Small Molecule
- Chemical Formula
- C8H10FN3O3S
- CAS Number
- 143491-57-0
- Unique Ingredient Identifier
- G70B4ETF4S
- Background
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults or combined with tenofovir alafenamide for the prevention of HIV-1 infection in high risk adolescents and adults. Emtricitabine is a cytidine analogue. The drug works by inhibiting HIV reverse transcriptase, preventing transcription of HIV RNA to DNA.
Emtricitabine was granted FDA approval on 2 July 2003.
- Indication
Emtricitabine is indicated in combination with other medications for the treatment of HIV-1 infections; treatment of HIV-1 infections in pediatric patients 25-35kg, treatment of HIV-1 infections in adult patients ≥35kg, for pre exposure prophylaxis of HIV-1 in adolescent and adult patients excluding those who have receptive vaginal sex; treatment of HIV-1 infections in pediatric and adult patients ≥17kg, pre exposure prophylaxis in adolescents and adults ≥35kg; treatment of HIV-1 in patients ≥12 years and ≥35kg; treatment of HIV-1 in patients weighing ≥35kg; treatment of HIV-1 in patients weighing ≥25kg; and treatment of HIV-1 in patients weighing ≥40kg.
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- Pre-Exposure Prophylaxis (PrEP)
A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Triangle Pharmaceuticals
- Registration Number
- NCT00006208
- Locations
- 🇺🇸
East Bay Clinical Trial Ctr, Concord, California, United States
🇺🇸Orange Coast Med Group, Newport Beach, California, United States
🇺🇸Health Positive, Safety Harbor, Florida, United States
A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Triangle Pharmaceuticals
- Registration Number
- NCT00002362
- Locations
- 🇺🇸
Northstar Med Clinic, Chicago, Illinois, United States
🇺🇸Houston Clinical Research Network, Houston, Texas, United States
🇺🇸Univ of Texas / Med School at Houston, Houston, Texas, United States
Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Triangle Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT00017992
- Locations
- 🇺🇸
USC School of Medicine / LA County Med Ctr, Los Angeles, California, United States
🇺🇸Univ of Miami, Miami, Florida, United States
🇲🇽Instituto Mexicano de Investigacion Clinica, Col Roma, Mexico
Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-05
- Target Recruit Count
- 43
- Registration Number
- NCT00016718
- Locations
- 🇵🇷
Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS, San Juan, Puerto Rico
🇺🇸Chicago Children's CRS, Chicago, Illinois, United States
🇺🇸Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States
A Study of HIV-Disease Development in Aging
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 90
- Registration Number
- NCT00006144
- Locations
- 🇺🇸
Santa Clara Valley Med. Ctr., San Jose, California, United States
🇺🇸Mt. Sinai Med. Ctr. A0404 CRS, New York, New York, United States
🇺🇸Columbia Univ., HIV Prevention and Treatment Medical Ctr., New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.